MedTrace Logo

SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

NCT03050229 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2018-03-27

No results posted yet for this study

Summary

To explore the beneficial effects of 'empagliflozin + ARB' in comparison with 'placebo + ARB' on the reduction of nocturnal blood pressure in T2DM with hypertension

Conditions

  • Nocturnal Hypertension
  • T2DM (Type 2 Diabetes Mellitus)

Interventions

DRUG

Empagliflozin

Empagliflozin 10mg/day once daily before or after breakfast

DRUG

Placebo

Placebo once daily before or after breakfast

Sponsors & Collaborators

Principal Investigators

  • Kazuomi Kario, MD · Jichi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-10-31
Completion
2018-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03050229 on ClinicalTrials.gov